- CEO
- Hong Yu Zhang
- Full Time Employees
- 856
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Anqing China
- IPO Date
- Jul 5, 2022
- Business
- Anhui Hongyu Wuzhou Medical Manufacturer Co., Ltd. is a China-based medical device company primarily engaged in the research, development, manufacturing, and global distribution of single-use sterile medical consumables and clinical injection supplies. Founded in 2011 and headquartered in Anqing, Anhui Province, China, the company is publicly listed on the ChiNext board of the Shenzhen Stock Exchange under the ticker symbol 301234.
The company operates across multiple dedicated product lines within the medical consumables sector, providing specialized product offerings: infusion and transfusion administration devices, including gravity infusion sets, precision filter infusion sets, blood transfusion sets, and scalp vein sets; injection and puncture equipment, encompassing conventional disposable sterile syringes, safety auto-disable syringes, insulin syringes, insulin pen needles, hypodermic needles, blood collection needles, and intravenous cannulas; and supplementary clinical diagnostic and protective consumables, including electronic sphygmomanometers, medical protective masks, surgical dressings, and catheter accessories. In addition to marketing proprietary branded products, the company delivers contract manufacturing, original equipment manufacturing, and original design manufacturing services to international medical equipment and pharmaceutical partners, operating under global regulatory standards including ISO 13485 quality management certification, European CE conformity, and United States FDA 510(k) product clearances.
The company caters to institutional healthcare clients, including general and specialized hospitals, clinical laboratories, blood centers, ambulatory surgical facilities, and multinational healthcare supply distributors. Geographically, while maintaining substantial market penetration across mainland China, the company derives a significant portion of its revenues from international markets, exporting products to more than 80 countries and regions across Europe, North America, South America, Asia, and Africa.
In recent corporate developments, the company announced a significant strategic asset acquisition to purchase 100% equity in Xuanzhi Electronic Technology (Shanghai) Co., Ltd. through a combined structure of share issuance and cash payment, accompanied by supporting capital fundraising to accelerate technological capabilities and business diversification. Concurrently, the company has expanded its advanced automated manufacturing lines in Anhui, accelerated the commercialization of high-value safety-engineered needle and pre-filled injection systems, and broadened international trade partnerships to navigate evolving global regulatory requirements and enhance its supply chain scale across overseas markets.